Heparin versus placebo for non-ST elevation acute coronary syndromes

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Andrade Castellanos, Carlos A ^a   Colunga Lozano, Luis E ^a   Delgado Figueroa, Netzahualpilli ^b   Magee, Kirk ^c  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT;

ALL CAUSE MORTALITY; BLEEDING; DEATH; DRUG EFFECT; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; QUALITY CONTROL; RECURRENT DISEASE; REVASCULARIZATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; MORTALITY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942804506     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003462.pub3     Document Type: Review

References (88)

1. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). American Journal of Cardiology 1990;66(19):1287-92.
2. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al.Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation 1994;89(1):81-9.
3. Doucet S, Malekianpour M, Theroux P, Bilodeau L, Cote G, Guise P, et al.Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation 2000;101(9):955-61.
4. Swahn E, Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). American College of Cardiology 1997;80:25E-29E.
5. Wallentin L. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347(9001):561-8.
6. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, et al.Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology 1995;26(2):313-8.
7. Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al.Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology 1994;24(1):39-45.
8. Wallentin L. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336(8719):830-7.
9. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al.Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine 1988;319(17):1105-11.
10. Averkov OV, Zateischikov DA, Gratsiansky NA, Logutov YA, Yavelov IS, Yanus VM. Unstable angina pectoris: aspirin and heparin in a double-blind placebo-controlled study, their effects on the outcojjme of disease during hospitalization. Kardiologiya 1993;33(5):4-9.
11. Bodo I, Nemeth C, Littmann L, Holdright DR, Fox KM. Heparin and aspirin in unstable angina: insufficient sample size may lead to erroneous conclusions. Journal of the American College of Cardiology 1995;25(2):553-4.
12. Borja J, Olivella P. Low molecular weigh heparin in the treatment of acute coronary syndromes without ST elevation: Unstable angina and non Q wave myocardial infarction [Hepariona de bajo peso molecular en el tratamiento de los sindromes coronarios agudos sin elevacion del segmento ST: angina inestable e infarto de miocardio sin onda Q]. Medicina Clinica 2000;115(15):583-6.
13. Borja J, Campbell y Pere Olivella J, Magda H. Dalteparin in the acute phase of unstable angina and non-Q-wave infarction [Dalteparina en la fase cronica de la angina inestable e infarto sin onda Q]. Revista Espanola de Cardiologia 2000;53(8):1147-8.
14. Borja J. Dalteparin for unstable angina and non-Q-wave myocardial infarction. Archives of Internal Medicine 2000;160(20):3169-70.
15. Brown KW, MacMillan RL. Initial heparin therapy in acute myocardial infarction. Canadian Medical Association Journal 1964;13(90):1345-8.
16. Charvat J, Kuruvilla T. Comparative study of heparin and antiplatelets in treatment of preinfarction angina. Cardiologia 1989;34:146-54.
17. Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, et al.Prospective comparison of unstable angina versus non-Q-wave myocardial infarction during antithrombotic therapy. Journal of the American College of Cardiology 1993;22(5):1338-43.
18. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, et al.The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. Journal of the American College of Cardiology 2003;42(8):1348-56.
19. Collins R, Baigent C, Peto R. Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA 1996;276:1873.
20. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al.Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375(9710):201-9.
21. Correia LC, Neubauer C, Azevedo A, Ribeiro F, Braga J, Passos LC, et al.The role of low molecular weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty [O papel da heparina de baixo peso do miocardio e pos-angioplastia percutanea transluminal coronaria eletiva.molecular na angina instavel, infarto agudo]. Arquivos Brasileiros de Cardiologia 1995;65(6):475-8.
22. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, et al.Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes inpatients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293(4):427-35.
23. Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction. Indian Heart Journal 2000;52:533-9.
24. Ferguson JJ, Zaqqa M. Platelet Glycoprotein IIb/IIa receptor antagonists current concepts and future directions. Drugs 1999;58:965-82.
25. Ragmin F, Wallentin L, Swahn E, Kontny F, Husted S, Lagerqvist B, et al.Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354(9180):701-7.
26. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 1988;77(5):1022-9.
27. Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, et al.GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336(8707):65-71.
28. Gorski J, Dmochowska-Wroblewska W. Heparin in myocardial infarction and unstable angina [Kliniki Chorob Zawodowych i Tropikalnych Instytutu Medycyny Morskiej i Tropikalnej, Gdyni]. Kardiologia Polska 1993;38(3):229-31.
29. Goy JJ. Contemporary approach to management of unstable angina. Lancet 1999;354:694-5.
30. Gulba DC. Heparin therapy in coronary heart disease [Heparin-therapie bei koronarer herzkrankheit]. Deutsche Medizinische Wochenschrift 1992;117(1):35-6.
31. Hasselblad V. Meta-analysis of multitreatment studies. Medical Decision Making 1998;18(1):37-43.
32. Huber K, Resch I, Rosc D, Probst P, Kaindl F, Binder BR. Heparin induced increase of T-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment. Thrombosis Research 1989;55:779-84.
33. Hurtado L, Adabache M, Escarcega FL, Cardenas M. Acute myocardial infarction treated with anticoagulants [Evolucion hospitalaria del infarto agudo del miocardio tratado con y sin anticoagulantes]. Archivos del Instituto de Cardiologia de Mexico 1984;54(5):463-70.
34. Jaffrani NA, Ehrenpreis S, Laddu A, Somberg J. Therapeutic approach to unstable angina: nitroglycerin, heparin, and combined therapy. American Heart Journal 1993;126:1239-42.
35. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin. Journal of the American College of Cardiology 2000;35:1699-712.
36. Kontny F. Improving outcomes in acute coronary syndromes - the FRISC II trial. Clinical Cardiology 2001;24(3 Suppl):I3-7.
37. Massel D, Cruickshank MK. Enoxaparin in acute coronary syndromes: Evidence for superiority over placebo or untreated control. American Heart Journal 2002;143(5):748-52.
38. Mattioli AV, Tarabini Castellani E, Goedecke L, Sormani L, Sternieri S, Mattioli G. Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study. Clinical Cardiology 1999;22(3):213-7.
39. Millonig-Gannjer. [Koronarer bypass: erfolg hangt oft von psyche ab]. Arch Medici Nr 1989;8:433-4.
40. Moise A, Roos M. Aspirin versus heparin in the acute phase of unstable angina. Circulation 1994;90:1107.
41. Montgomery HE, Chester MR. Heparin in unstable angina. Lancet 1995;346:248.
42. Nardelli A, Bottero G, De Francesco A. Study on the efficacy of heparin and aspirin in unstable angina and acute heart infarction [Cosa hanno insegnato i grandi trials sull'eparina e sull'aspirina nell'angina instablile e nell'infarto miocardico acuto]. Clinica e Terapia Cardiovascolare 1991;10(3):171-7.
43. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al.Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295(13):1519-30.
44. Ocampo S, Solorio S, Rangel A, Leon FJ, Lepe L, Ayala F, et al.Low molecular weight heparin in unstable angina pectoris [La heparina de bajo peso molecular en la angina de pecho inestable]. Archivos del Instituto de Cardiologia de Mexico 1999;69:222-7.
45. Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, et al.Effects of fondaparinux in patients withST-segment elevation acute myocardial infarction not receiving reperfusion treatment. European Heart Journal 2008;29(3):315-23.
46. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-5.
47. Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, et al.Prognostic Importance of ConcomitantHeparin With Eptifibatide in AcuteCoronary Syndromes. American Journal of Cardiology 2001;87(5):532-6.
48. Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104(23):2772-7.
49. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Annals of Internal Medicine 1993;119:874-81.
50. Rubio-Terres C, Pajuelo F, Margalet I. Low-molecular-weight heparins in unstable angina and non-Q-wave myocardial infarction [Heparinas de bajo peso molecular en la angina inestable y el infarto de miocardio sin onda Q]. Medicina Clinica 2001;116(16):638-9.
51. Sayen JJ, Singer RB, Peirce G, Horwitz O. Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20, 000 units/day) in the treatment of patients with acute coronary event - first year and long-term comparative mortality. Transactions of the American Clinical & Climatological Association 1982;94:141-53.
52. Serneri GGN, Abbate R, Prisco D, Carnovali M, Fazi A, Casolo GC, et al.Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin: a controlled cross-over randomized study. American Heart Journal 1988;115:60-6.
53. Serneri GGN, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, et al.Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990;335:615-8.
54. Serneri GGN, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L, et al.Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995;345(8959):1201-4.
55. Spodick DH. Aspirin, heparin, or both to treat unstable angina. New England Journal of Medicine 1989;320:1014.
56. Tanajura LFL, Sousa AGMR, Pinto IMF, Chaves AJ, Centemero MP, Feres F, et al.Use of heparin in coronary angioplasty: randomized trial in low risk patients for abrupt closure [Heparina na Angioplastia Coronária. Estudo Randomizado emCasos com Baixo Risco Para Oclusão Aguda]. Arquivos Brasileiros de Cardiologia 1993;60(2):95-8.
57. Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, et al.The TETAMI Trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. Journal of Thrombosis & Thrombolysis 2000;10:241-6.
58. Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88(5 Pt 1):2045-8.
59. Thieuleux FA, Vilarem D, Lablanche JM, Asseman PA, Thery C, Bertrand ME. Management of unstable angina pectoris with maximal medical treatment (combination of intravenous nitrates, beta-blockers, calcium antagonists and heparin). Bibliotheca Cardiologica 1985;39:88-96.
60. Umans VA, Kloeg PH, Bronzwaer J. The CAPTURE trial. Lancet 1997;350:445.
61. Violaris AG, Campbell S. Low-dose aspirin and heparin in unstable coronary artery disease. Lancet 1991;337:489-90.
62. Wallentin L, Husted S, Kontny F. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II study). American Journal of Cardiology 1997;80:61E-63E.
63. Wallis DE, Boden WE, Califf R, Crawford MH, Hakki AH, Iskandrian AS, et al.Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. American Heart Journal 1991;122:949-54.
64. Zwerner P, Gore J, Corrao J, et al.Heparin in the treatment of unstable angina: a randomized prospective trial. Circulation 1987;76(Suppl IV):IV-180.
65. Anderson JL, Adams CD, Antman EM, Bridges CR, CaliffRM, Casey DE Jr, et al.2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines. Journal of the American College of Cardiology 2013;61(23):e179-347.
66. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al.One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. Journal of the American College of Cardiology 1995;26(7):1643-50.
67. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. American Journal of Cardiology 2008;101(7):960-6.
68. Cairns JA, J Singer, M Gent, Holder DA, Rogers D, Sackett DL, et al.One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or chest pain in Hamilton, Ontario, a city of 375, 000 people. Canadian Journal of Cardiology 1989;319:239-46.
69. Cohen M. Approaches to the treatment of unstable angina and non-Q wave myocardial infarction. Canadian Journal of Cardiology 1998;14(Suppl E):11E-14E.
70. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1987;7(3):177-88.
71. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355(9219):1936-42.
72. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011;32(23):2999-3054.
73. Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Annals of Internal Medicine 2007;146(6):434-41.
74. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657-71.
75. Higgins JP, Thompson SG, Deek JJ, Altman DG. Bias in meta-analysis detected by a simple, graphical test. BMJ 2003;327:557-60.
76. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Chichester (UK): John Wiley & Sons, 2011.
77. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114:489S-510S.
78. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, et al.Proctective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results for a Veterans Administration Cooperative Study. New England Journal of Medicine 1983;309(7):396-403.
79. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
80. Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002132]
81. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clinical Cardiology 2007;10(2):II24-34.
82. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al.Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011;342:d4002.
83. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89(4):1545-56.
84. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine 2003;163(20):2518-24.
85. Weitz JE. Low molecular weight heparins. New England Journal of Medicine 1997;337:688-98.
86. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345(7):494-502.
87. Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, et al.Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PloS One 2012;7(2):e316242.
88. Magee K, Campbell SG, Moher D, Rowe BH. Heparin versus placebo for acute coronary syndromes. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD003462.pub2]